DMT210 Topical Gel in the Treatment of Atopic Dermatitis
Launched by DERMATA THERAPEUTICS · Oct 27, 2016
Trial Information
Current as of June 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female 12 years or older
- • Patient has chronic, stable AD that has been present for at least 3 months with 5-35% (inclusive) BSA (Body Surface Area) of AD involvement
- • Patient has two analogous, Target Lesions; one lesion within each of the two Treatment Areas
- • Patient is willing and able to comply with the protocol
- Exclusion Criteria:
- • Patient has used topical therapies for AD within the Treatment Areas 2 weeks before baseline
About Dermata Therapeutics
Dermata Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological conditions. With a commitment to addressing unmet medical needs, Dermata utilizes its proprietary platform technology to create novel treatments that enhance patient outcomes and improve quality of life. The company is dedicated to advancing its pipeline through rigorous clinical trials, collaborating with healthcare professionals and regulatory bodies to bring safe and effective solutions to the market.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Norfolk, Virginia, United States
Patients applied
Trial Officials
Christopher Nardo, PhD
Study Director
Dermata Therapeutics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials